Skip to main content

Advertisement

SpringerLink
Log in

Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The female predominance in meningioma incidence and association between meningioma and breast cancer suggest that growth of meningiomas is hormone-dependent. There are several discrepancies in literature about the proliferative effect of sex hormones on meningiomas. This study aims to evaluate the hormone receptor status of meningiomas and assess its relation to age, sex, histological grade, recurrence, and proliferation activity. The material was based on consecutive patients operated for meningioma at Tampere University Hospital in 1989–1999. The occurrence of progesterone, estrogen and androgen receptor in patients with primary and recurrent meningiomas was studied immunohistochemically by using specific monoclonal antibodies. Hormonal status was determined in 510 tumor samples. 443 samples were from primary meningiomas and 67 from recurrent tumors. Of the␣samples, 455 were benign (WHO grade I), 49 atypical (grade II), and 6 malignant (grade III). Of the primary tumor samples, 88% were progesterone receptor positive, 40% were positive for estrogen and 39% for androgen receptors. Grade I meningiomas had significantly higher incidence for estrogen and androgen receptors than higher grade meningiomas. Estrogen positive tumor samples had significantly higher proliferation index than estrogen negative samples. No difference in expression of sex hormone receptors was observed by sexes or age group. Estrogen and androgen receptors may have more influence on the pathogenesis of meningiomas than earlier thought. The higher incidence of meningiomas in women can not be␣explained by differences of sex hormone receptor expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abramovich CM, Prayson RA (1998) MIB-1 labeling indices benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol 29:1420–1427

    Article  PubMed  CAS  Google Scholar 

  2. Adams EF, Schrell UM, Fahlbusch R, Thierauf P (1990) Hormonal dependency of cerebral meningiomas. Part 2:In vitro effect of steroids, bromocriptine, and epidermal growth factor ofmeningiomas. J Neurosurg 73:750–755

    PubMed  CAS  Google Scholar 

  3. Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, Inai K (2001) Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 32:970–975

    Article  PubMed  CAS  Google Scholar 

  4. Bickerstaff ER, Small JM, Guest IA (1958) The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 21:89–91

    PubMed  CAS  Google Scholar 

  5. Black P, Carroll R, Zhang J (1996) The molecular biology of hormone and growth factor receptors in meningiomas. Acta Neurochir 65(Suppl):50–53

    CAS  Google Scholar 

  6. Blankenstein MA, Blaauw G, Lamberts SWJ (1984) Progestin and estrogen receptors in human meningioma. Clin Neuropharmacol 7:363–367

    PubMed  CAS  Google Scholar 

  7. Bouillot P, Pellissier JF, Devictor B, Graziani N, Bianco N, Grisoli F, Figarella-Branger D (1994) Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data. J Neurosurg 81:765–773

    PubMed  CAS  Google Scholar 

  8. Bozzetti C, Camisa R, Nizzoli R, Manotti L, Guazzi A Naldi N, Mazza S (1995) Estrogen and progesterone receptors in human meningiomas: biochemical and immunocytochemical evaluation. Surg Neurol 43:230–234

    Article  PubMed  CAS  Google Scholar 

  9. Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H (1993) Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery 33:212–218

    PubMed  CAS  Google Scholar 

  10. Carrol RS, Glowacka D, Dashner K, Black PM (1993) Progesterone receptor expression in meningiomas. Cancer Res 53:1312–1316

    Google Scholar 

  11. Carrol RS, Zhang J, Dashner K, Sar M, Wilson EM, Black P (1995) Androgen receptor expression in meningiomas. J Neurosurg 82:453–460

    Google Scholar 

  12. Carrol RS, Zhang J, Dashner K, Black P (1995) Progesterone and glucocorticoid receptor activation in meningiomas. Neurosurgery 37:92–97

    Article  Google Scholar 

  13. Carroll RS, Zhang J, Black P (1999) Expression of estrogen receptors alpha and beta in human meningiomas. J Neuro-Oncol 42:109–116

    Article  CAS  Google Scholar 

  14. Carrol RS, Brown M, Zhang J, DiRenzo J, Font de Mora J, Black PM (2000) Expression of a subset of steroid receptor cofactors is associated with progesterone receptor epression in meningiomas. Clin Cancer Res 6:3570–3575

    Google Scholar 

  15. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357–363

    Article  PubMed  CAS  Google Scholar 

  16. Christensen HC, Kosteljanetz M, Johansen C (2003) Incidences of gliomas and meningiomas in Denmark, 1943 to 1997. Neurosurgery 52:1327–1334

    Article  PubMed  Google Scholar 

  17. Custer BS, Koepsell TD, Mueller BA (2002) The associaton between breast carcinoma and meningioma in women. Cancer 94:1626–1635

    Article  PubMed  CAS  Google Scholar 

  18. Fewings PE, Battersby RD, Timperley WR (2000) Long-term follow-up of progesterone receptor status in benign meningioma: a prognonstic indicator of recurrence? J Neurosurg 92:401–405

    PubMed  CAS  Google Scholar 

  19. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsen JJ (1993) A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neuro-oncol 15:75–77

    Article  CAS  Google Scholar 

  20. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci L, Stevenson LL (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861–866

    PubMed  CAS  Google Scholar 

  21. Hana V, Murphy LJ (1994) Interdependence of epidermal growth factor and insulin-like growth factor-I expression in the mouse uterus. Endocrinology 135:107–112

    Article  PubMed  CAS  Google Scholar 

  22. Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113–120

    PubMed  CAS  Google Scholar 

  23. Hsu DW, Efird JT, Hedley-Whyte ET (1998) MIB-1 (Ki-67) index and transfoming growth factor-alpha (TGFα) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol App Neurobiology 24:441–452

    Article  CAS  Google Scholar 

  24. Jhawar BS, Fuchs CS, Colditz GA, Stamper MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853

    Article  PubMed  CAS  Google Scholar 

  25. Jääskeläinen J, Haltia M, Servo A (1986) Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25:233–242

    Article  PubMed  Google Scholar 

  26. Karamitopoulou E, Perentes E, Tolnay M, Probst A (1998) Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 29:140–145

    Article  PubMed  CAS  Google Scholar 

  27. Khalid H (1994) Immunohistochemical study of estrogen receptor related antigen, progesterone and estrogen receptors in human intracranial meningiomas. Cancer 74:679–685

    Article  PubMed  CAS  Google Scholar 

  28. Kleihues P, Burger PC, Scheithauer B (1993) The new WHO classification of brain tumors. Brain Pathol 3:255–268

    PubMed  CAS  Google Scholar 

  29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 7:844–847

    Article  Google Scholar 

  30. Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C, Patsouris E (2003) Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43:280–290

    Article  PubMed  CAS  Google Scholar 

  31. Lamberts SW, Tange HL, Avezaat CJ, Braakman R, Wijngaarde R, Koper JW, de Jong H (1992) Mifepristone (RU486) treatment of meningiomas. J Neurol Neurosurg Psychiat 55:486–490

    Article  PubMed  CAS  Google Scholar 

  32. Marks SM, Whitewell HL, Lye RH (1986) Recurrence of meningiomas after operation. Surg Neurol 25:436–440

    Article  PubMed  CAS  Google Scholar 

  33. Markwalder TM, Seiler RW, Zava DT (1985) Antiestrogenic therapy of meningiomas- a pilot study. Surg Neurol 24:245–249

    Article  PubMed  CAS  Google Scholar 

  34. Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T (1994) Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 80:527–534

    PubMed  CAS  Google Scholar 

  35. Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, et al (1996) Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 91:504–510

    Article  PubMed  CAS  Google Scholar 

  36. Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades HN (1993) Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 78:456–462

    PubMed  CAS  Google Scholar 

  37. Miller RE (1986) Breast cancer and meningioma. J Surg Oncol 31:182–183

    PubMed  CAS  Google Scholar 

  38. Nagashima G, Aoyagi M, Wakimoto H, Tamaki M, Ohno K, Hirakawa K (1995) Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery 37:478–483

    PubMed  CAS  Google Scholar 

  39. Nakamura M, Roser F, Michel J, Jacobs C, Samii M (2003) The natural history of incidental meningiomas. Neurosurgery 53:62–71

    Article  PubMed  Google Scholar 

  40. Nakasu S, Hirano A, Shimura T, Llena JF (1987) Incidental meningiomas in autopsy study. Surg Neurol 27:319–322

    Article  PubMed  CAS  Google Scholar 

  41. Nakasu S, Nakajima M, Matsumura K, Nakasu Y, Handa J (1995) Meningioma: proliferative potential and clinicoradiological features. Neurosurgery 37:1049–1055

    PubMed  CAS  Google Scholar 

  42. Olson JJ, Beck DW, Schlechte J, Loh P-M (1986) Hormonal manipulation of meningiomas in vitro. J Neurosurg 65:99–107

    PubMed  CAS  Google Scholar 

  43. Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, et al (2000) Regression of a presumed meningioma with the antiestrogen agent mepitiostane: case report. J Neurosurg 93:132–135

    Article  PubMed  CAS  Google Scholar 

  44. Perrot-Applanat M, Groyer-Picard MT, Kujas M (1992) Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir 115:20–30

    Article  CAS  Google Scholar 

  45. Reynolds RK, Talavera F, Roberts JA, Hopkins MP, Menon KMJ (1990) Regulation of epidermal growth factor and insulin-like growth factor I receptors by estradiol and progesterone in normal and neoplastic endometrial cell cultures. Gynecol Oncol 38:396–406

    Article  PubMed  CAS  Google Scholar 

  46. Roelvinck NCA, Kamphorst W, van Alphen HAM, Rao R (1987) Pregnancy-related primary brain and spinal tumors. Arch Neurol 44:209–215

    Google Scholar 

  47. Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M (2004) The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 57:1033–1037

    Article  PubMed  CAS  Google Scholar 

  48. Rubinstein AB, Loven D, Geier A, Reichental E, Gadoth N (1994) Hormone receptors in initially excised versus recurrent intracranial meningiomas. J Neurosurg 81:184–187

    PubMed  CAS  Google Scholar 

  49. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola J, Helin HJ (1994) Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275–282

    Article  PubMed  CAS  Google Scholar 

  50. Schoenberg BS, Christine BW, Wisnant JP (1975) Nervous system neoplasms and primary malignances of other sites. The unique association between meningiomas and breast cancer. Neurology 25:705–712

    PubMed  CAS  Google Scholar 

  51. Schrell UMH, Adams EF, Fahlbusch R, Greb R, Jirikowski G, Prior R, Ramalho-Ortigao FJ (1990) Hormonal dependency of cerebral meningiomas. Part 1: female sex steroid receptors and their significance as specific markers for adjuvant medical therapy. J Neurosurg 73: 743–749

    PubMed  CAS  Google Scholar 

  52. Tonn JC, Ott MM, Bouterfa H, Kerkau S, Kapp M, Müller-Hermelink HK, Roosen K (1997) Inverse correlation of cell proliferation and expression of progesterone receptors in tumor spheroids and monolayer cultures of human meningiomas. Neurosurgery 41:1152–1159

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Sari Toivola, Salla Kolmihaara, Paula Kaukoranta, and Anssi Lagerstedt for their excellent techincal assistance.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University Hospital of Turku, PO Box 52, 20520 , Turku, Finland

    Katariina Korhonen

  2. School of Public Health, University of Tampere, Tampere, Finland

    Tiina Salminen, Jani Raitanen & Anssi Auvinen

  3. Laboratory of cancer biology, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland

    Jorma Isola

  4. Department of Pathology, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland

    Hannu Haapasalo

Authors
  1. Katariina Korhonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tiina Salminen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jani Raitanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anssi Auvinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jorma Isola
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hannu Haapasalo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katariina Korhonen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korhonen, K., Salminen, T., Raitanen, J. et al. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80, 1–7 (2006). https://doi.org/10.1007/s11060-006-9146-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-006-9146-9

Keywords

Search

Navigation